AstraZeneca PLC
AZN
$187.03
-$2.72-1.43%
NYSE
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | 5.62% | 55.07% | 77.26% | 27.14% | 33.82% |
| Total Depreciation and Amortization | 6.39% | 85.71% | -14.75% | 8.60% | 2.31% |
| Total Amortization of Deferred Charges | -- | 18.00% | -- | -- | -- |
| Total Other Non-Cash Items | -42.62% | -120.39% | 126.04% | -1,450.00% | 87.63% |
| Change in Net Operating Assets | -134.74% | -243.14% | 1,936.59% | -167.44% | 6.37% |
| Cash from Operations | -9.53% | -19.44% | 51.76% | 9.76% | 49.36% |
| Capital Expenditure | -27.51% | -46.33% | -64.51% | -72.51% | -2.88% |
| Sale of Property, Plant, and Equipment | 700.00% | 50.00% | -- | -- | -98.11% |
| Cash Acquisitions | 29.01% | 0.36% | -24.71% | 88.38% | 61.81% |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -115.12% | 30.35% | -18.35% | -517.10% | 57.95% |
| Cash from Investing | -43.02% | -22.44% | -32.17% | 26.60% | 48.07% |
| Total Debt Issued | 293.45% | -76.92% | 15.18% | -57.12% | -81.61% |
| Total Debt Repaid | -12.94% | -1,671.43% | 95.54% | 95.76% | -4.94% |
| Issuance of Common Stock | 25.00% | 0.00% | 25.00% | -20.00% | 33.33% |
| Repurchase of Common Stock | -25.93% | -- | 76.54% | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | 1.79% | -- | -2.22% | 41.18% | -10.35% |
| Other Financing Activities | -169.23% | -1,178.26% | -112.50% | -- | 112.37% |
| Cash from Financing | 109.86% | -389.12% | 49.82% | 142.39% | -233.48% |
| Foreign Exchange rate Adjustments | -172.00% | 106.56% | -160.00% | 583.33% | 154.35% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 918.02% | -339.64% | 146.74% | 279.80% | -110.80% |